Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Galantamine and Memantine for Cognitive Impairments in Schizophrenia
NCT02234752Phase 2Terminated
- Sponsor
- Sheppard Pratt
- Start
- Sep 2014
- Primary completion
- Jul 2016
- Modality
- Nucleic Acid-Directed Small Molecules, Classical Binding Small Molecules, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
A Phase 2 trial of galantamine, memantine in schizophrenia, schizoaffective disorder, sponsored by Sheppard Pratt. Started Sep 2014; status: terminated.
02
Drugs
galantaminememantine
03
Conditions
schizophreniaschizoaffective disorder
Beyond the preview
Go deeper on NCT02234752.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02234752.